Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncological and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for c-Fos drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | c-Fos Recombinant Protein High purity (>90%), Endotoxin controlled. Sequence Verified. Available with His/GST tags for protein-protein interaction (PPI) screening. |
View c-Fos Products |
| Gene Delivery | c-Fos Promise-ORF / Lentivirus Full-length ORF for stable reporter cell line construction (AP-1 activation assays). |
View c-Fos Products |
| Benchmark Ab | Anti-c-Fos Antibody Recombinant positive control for western blot, ChIP, and immunofluorescence. |
View c-Fos Products |
| Validator | c-Fos siRNA Set For target knockdown verification and specificity profiling. |
View c-Fos Products |
| Related Target A | c-Jun Dimerization partner of c-Fos forming the AP-1 transcription factor complex. Essential for PPI inhibition assays. |
View c-Jun Products |
| Related Target B | AP-1 The functional heterodimeric complex. Crucial for downstream target gene reporter assays. |
View AP-1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Transcription Factor Dimerization Screening | Full-length c-Fos and c-Jun partner proteins with precise tag configurations (GST/His) for robust HTRF/FP assays. |
| High-Throughput Reporter Assays | High-titer Lentivirus containing c-Fos/AP-1 response elements for rapid stable cell line generation. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies included in the portfolio. |
| False Positives in Small Molecule Screens | Validated siRNA sets included for orthogonal target knockdown verification. |
Live c-Fos/FOS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for c-Fos therapeutics is intensifying, with major players shifting focus from traditional upstream MAPK/ERK pathway inhibitors to direct transcription factor disruption via small molecule protein-protein interaction (PPI) inhibitors and PROTACs. As first-generation indirect therapies reach clinical boundaries due to systemic toxicity, the next wave of R&D is targeting the specific dimerization interface of the c-Fos/c-Jun (AP-1) complex to achieve oncogenic selectivity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI) | Academic Institutes, Biotech Startups | Solid Tumors, Osteosarcoma | Dimerization Inhibition Assay (Need high-purity c-Fos/c-Jun recombinant proteins) |
| PROTAC / Degrader | Targeted Protein Degradation (TPD) Pioneers | Hematological Malignancies, Drug-Resistant Cancers | Ubiquitination & Degradation Assays (Need sequence-verified c-Fos with functional tags) |
| Gene Therapy / siRNA | RNAi Therapeutics Developers | Inflammatory Diseases, Rheumatoid Arthritis | Target Knockdown Validation (Need validated c-Fos siRNA sets) |